Lymph

Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy

Positive interim results prompt request for meeting with FDA SEATTLE, July 11, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced today that interim results ofits phase II/III trial comparing CPOP-R, in which pixantrone issubstituted for doxorubicin in standard CHOP-R first-line treatmentof patients with aggressive non-Hodgkin's lymphoma (NHL), resultedin essentially al...

Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - BiovestInternational, Inc. (OTCBB: BVTI), a majority owned subsidiary ofAccentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June27, 2007 blinded interim data from the start of its fast-trackedpivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin'slymphoma (NHL) from September 2000 through June 2006. This interimblinded dat...

Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation(OTCBB:NEOP), a diversified developer of innovative oncology andcardiovascular surgical and diagnostic products, today announcedpositive preliminary results from a multicenter Phase 2 clinicalstudy of its lead clinical candidate, Lymphoseek(R) (TechnetiumTc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietaryradioactive tar...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

- Results Presented at the 12th Congress of European HematologyAssociation (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that data presented at the 12th Congressof EHA in Vienna, Austria, showed positive responses in patie...

Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe

Data Reported at the Congress of the European HematologyAssociation SAN DIEGO, June 11, 2007 /PRNewswire-FirstCall/ -- Favrille,Inc. , a biopharmaceutical company developing patient-specific,active immunotherapies for the treatment of cancer, announcedinterim data from a Phase 2 clinical trial of FavId(R) in patientswith indolent B-cell non-Hodgkin's lymphoma (NHL). The data werereported...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients ReducesSeverity of Adult Leukaemia Copenhagen, 6th June 2007 - Santaris Pharma, the Danishbiopharmaceutical company, announced today that SPC2996, theCompany's new RNA Antagonist of Bcl-2, has shown early evidence ofefficacy in an initial Phase I/II clinical study in ChronicLymphocytic Leukaemia (CLL). The results of the study...

Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - GloucesterPharmaceuticals, Inc., a privately held cancer therapeuticsdevelopment company, today announced that data for romidepsin as atreatment for cutaneous T-cell lymphoma (CTCL) and peripheralT-cell lymphoma (PTCL) were presented at the American Society ofClinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.The data presented...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)

Preliminary Results of Largest Randomized, Placebo-controlled TrialEver Conducted in CTCL Presented at the American Society ofClinical Oncology CHICAGO, June 04, 2007 /PRNewswire/ -- Preliminary results ofthe largest randomized, placebo-controlled clinical trial everconducted in patients with cutaneous T-cell lymphoma (CTCL) showedthat ONTAK was more than twice as effective as placebo in...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, NJ – June 4, 2007 – GentaIncorporated (Nasdaq: GNTA) announced the presentation of resultsfrom a Phase 2 clinical trial of its marketed product, Ganite®(gallium nitrate injection), plus rituximab (Rituxan®;Genentech/IDEC) and dexamethasone in patients with relapsed orrefractory non-Hodgkin’s lymphoma (NHL). The data werepresented at the annual mee...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia

SEATTLE, June 04, 2007 /PRNewswire-FirstCall/ -- ZymoGenetics,Inc. today announced that interim findings were presented from aPhase 1b clinical trial with atacicept in B-cell chroniclymphocytic leukemia (B-CLL) at the American Society of ClinicalOncology (ASCO) 2007 annual meeting. The study included intravenousadministration of higher doses than had been tested in previousstudies. <...

Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ --Genta Incorporated announced the presentation of results from aPhase 2 clinical trial of its marketed product, Ganite(R) (galliumnitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) anddexamethasone in patients with relapsed or refractory non-Hodgkin'slymphoma (NHL). The data were presented at the annual meeting of...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patientsare alive today due to MabThera BASEL, Switzerland, June 4, 2007-A follow-up analysis trackingthe outcome of patients with aggressive non-Hodgkin's lymphoma(NHL) who were treated with the innovative cancer therapy MabThera(rituximab) over seven years ago has revealed exciting results(1). This analysis of the original...

Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2007 - GloucesterPharmaceuticals, Inc., an oncology focused biopharmaceuticalcompany, announced today that the U.S. Food and Drug Administration(FDA) has granted Fast Track designation for its novel histonedeacetylase inhibitor, romidepsin, for the monotherapy ofpreviously treated peripheral T-cell lymphoma (PTCL). The Companyhad previously announc...

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

Adding MabThera to first line chemotherapy significantlyincreases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study publishedyesterday in the Journal of Clinical Oncology, MabThera (rituximab)plus chemotherapy (MCP*) was shown to significantly improvesurvival in patients with follicular lymphoma (FL) compared tochemotherapy alone.1 Follicular lymphoma is the...

Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X BiotechnologiesInc. announced today that a report published in the journal Blooddemonstrated that its lead compound, obatoclax (GX15-070), inducedcell death in vitro in Mantle Cell Lymphoma (MCL) cell lines andprimary cells from 11 MCL patients. Obatoclax (GX15-070) is a smallmolecule specifically designed to inhibit all relevant members oft...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...

Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research AnnualMeeting SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille,Inc. , a biopharmaceutical company developing patient-specific,active immunotherapies for the treatment of cancer, announcedresults from a new study showing enhanced activity from insect-cellderived idiotype (Id) proteins, a key component in the Company'sId...

Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies

- New Studies Confirm That Fusion Proteins Made by CombiningCytokines With Peregrine's Anti-PS Antibodies Demonstrate IncreasedAnti-Tumor Activity With No Observable Toxicity - LOS ANGELES and TUSTIN, Calif., April 18, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of canc...

ProNAi Announces Preclinical Success for PNT2258 Therapeutic - Curative Events in Xenograft Mice for Difficult-to-Treat Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics,Inc., a biopharmaceutical company pioneering a new class ofnucleic-acid drugs based on DNA interference (DNAi), todayannounced that its lead oncology therapeutic candidate, PNT2258,has successfully demonstrated preclinical in vivo efficacy inxenograft mice for a number of human cancers - including curativeevents for difficult-...

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Article Published in Recent Issue of Journal Blood NEW YORK, April 11, 2007 /PRNewswire-FirstCall/ -- CallistoPharmaceuticals, Inc. (FWB: CA4), a developer of new drugtreatments in the fight against cancer and other major healththreats, announced today the publication of a research article onAtiprimod, Callisto's drug currently in clinical trials incarcinoid cancer and multiple myeloma pa...

Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

SOUTH SAN FRANCISCO, Calif., April 11, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayprovided a clinical update on R788, which is currently in ongoingPhase 2 clinical trials in immune thrombocytopenic purpura (ITP),rheumatoid arthritis (RA) and lymphoma patients. R788 is a novel,oral syk kinase inhibitor that blocks the activation of mast cells,macrophages and B-cells th...

ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH

PUNTA DEL ESTE, Uruguay--(BUSINESS WIRE)--Mar 23, 2007 - ZIOPHARMOncology, Inc. (NASDAQ: ZIOP) announced today the presentation ofdata on ZIO-201 at the XXXI World Congress of the InternationalSociety of Hematology (ISH) meeting being held in Punta del Este,Uruguay. ZIO-201 is a proprietary form of the therapeutic activemetabolite of ifosfamide (IFOS), a drug that is widely used in thetreat...